WO2021170380A1

WO2021170380A1 - Improved preparation

Info

Publication number: WO2021170380A1
Application number: PCT/EP2021/052903
Authority: WO
Inventors: Caroline PLEHN
Original assignee: Beiersdorf Ag
Priority date: 2020-02-28
Filing date: 2021-02-08
Publication date: 2021-09-02
Also published as: EP4110272A1; DE102020202565A1

Abstract

The invention relates to a preparation for furniture polish.

Description

Improved preparation

Sweat is a watery secretion released from the human skin via so-called sweat glands. There are three types of sweat glands in the skin, namely apocrine, eccrine, and apoecrine sweat glands (Int J Cosmet Sci. 2007 Jun; 29 (3): 169-79).

In humans, the eccrine sweat glands are practically distributed over the entire body and can produce considerable quantities of a clear, odorless secretion that is more than 99% water. In contrast to this, the apocrine sweat glands only occur in the hairy areas of the body of the armpit and genital region as well as on the nipples. They produce small amounts of a milky secretion that contains proteins and lipids.

Sweating, also known as perspiration, is an effective mechanism for releasing excess heat and thereby regulating body temperature. The voluminous watery secretion of the eccrine glands, which in adults can produce up to 2-4 liters per hour or 10-14 liters per day, is used for this purpose.

The sweat - especially the secretion of the apocrine sweat glands - is also assigned a signaling effect via the sense of smell. In humans, apocrine sweat plays a role particularly in connection with emotional or stress-related sweating.

Cosmetic antiperspirants or deodorants are used to eliminate body odor or to reduce its development. Body odor occurs when fresh sweat, which is odorless, is broken down by microorganisms such as staphylococci and corynebacteria.

In common usage, there is not always a clear distinction between the terms “deodorant” and “antiperspirant”. Rather - especially in German-speaking countries - products for use in the armpit area are generally referred to as "deodorants". This happens regardless of the question of whether there is also an antiperspirant effect. Antiperspirants (AT) are antiperspirants that are supposed to prevent the secretion of sweat in the first place. Aluminum salts are used as active antiperspirant ingredients. These inhibit the flow of sweat by clogging the ducts of the sweat glands by precipitating on site together with the skin's own proteins and thus leading to so-called plugs.

In contrast to antiperspirants, pure deodorants do not actively influence sweat secretion, but only control or influence the body or armpit odor (odor improvers). The odor of sweat consists largely of branched-chain fatty acids that are released from odorless sweat by bacterial enzymes. Classic deodorant active ingredients counteract this, for example by reducing the growth of bacteria. It is also possible to neutralize odors by masking with perfume substances.

By definition, a product is referred to as an antiperspirant or an antiperspirant cosmetic composition if it comprises an antiperspirant active ingredient in a sweat-regulating concentration. Sweat regulation, as described, is to be expected when using aluminum salts, for example, as a rule from a concentration of 2% by weight.

By definition, a product is referred to as a deodorant or deodorant cosmetic composition / preparation if it does not contain aluminum salts and / or has no antiperspirant activity. This means that the flow of sweat is not actively hindered. The product, on the other hand, contains agents that improve odor if the product is used on the armpit skin.

The present invention relates to a deodorant cosmetic preparation.

One form of application of deodorant products are roll-ons, in which a liquid deodorant cosmetic preparation is transferred from a reservoir to a ball in a first step and the preparation is transferred to the skin in a second step by rolling the ball over the human skin . As a result, roll-on applicators have a reservoir in which the preparation to be applied is contained and a freely rotatable ball which is in fluid connection with the preparation inside the reservoir and is designed so that the preparation can be rotated by rotating the ball can be removed from the reservoir as a film on the surface of the sphere. For aesthetic reasons in particular, consumers mostly prefer roll-on products in which the preparation is transparent. This topic is already addressed for antiperspirant preparations, inter alia, in EP 0964671 B1 and WO 2005105027 A1.

However, the provision of such aqueous preparations is problematic. Conventional aqueous deodorant preparations, for example, often contain liquid perfumes, which have to be stably dissolved in the aqueous formulation. For this purpose, ethoxylated derivatives are usually used as solubilizers, in particular PEG-40 Hydrogenated Castor Oil. However, consumers increasingly prefer products which do not contain PEG derivatives, so that there is a need for alternative methods for the transparent dissolution of liquid perfumes.

As an alternative to PEG derivatives, it is also possible to use increased concentrations of ethanol as a solubilizer for liquid perfumes, so that a transparent formula is obtained. Such aqueous-alcoholic deodorant products are perceived by the consumer as fresh and cooling, but at the same time have a number of disadvantages. For example, application on freshly shaved skin is associated with intolerance due to the alcohol content. In addition, the skin often feels sticky after the ethanol has evaporated, which should be avoided.

Last but not least, many transparent formulas are based on the use of silicone oils. However, consumers increasingly prefer products that do not contain silicone oils, so that there is a need for alternative methods for the transparent dissolution of liquid perfumes.

In addition to high transparency, it is also crucial that a preparation is obtained which does not show any phase separation to the human eye. Otherwise, uniform application with a roll-on would only be more difficult because, depending on the current separation of the phases, sometimes more of one phase is applied than the other. Consequently, as the roller is emptied, no uniform effectiveness is achieved.

Consequently, there is still a need for deodorant preparations which have a high level of transparency in the visible spectrum and in which no or less phase separations or deposits occur which can be recognized by the human eye.

Surprisingly, the present invention was able to address these issues. A first subject of the present invention is an aqueous cosmetic deodorant preparation comprising a) zinc ricinoleate, b) at least one complexing agent, and c) caprylyl / caprylic glucoside and / or sodium methyl cocoyl taurate.

A second subject of the invention is the use of the combination of zinc ricinoleate, at least one complexing agent and at least one substance selected from caprylyl / caprylic glucoside and sodium methyl cocoyl taurate as a solubilizer in an aqueous cosmetic preparation.

If weight percentages (% by weight) are given below without reference to a specific composition / preparation or specific mixture, then this information always relates to the total weight of the above-mentioned composition / preparation. If ratios of components / substances / groups of substances are disclosed below, these ratios relate to weight ratios of the components / substances / groups of substances mentioned.

Unless otherwise stated, all tests and process steps were carried out under normal conditions. The term “normal conditions” means 20 ° C, 1013 hPa and a relative humidity of 50%.

If viscosity values are given in this disclosure, then all values relate to a measurement at 25 ° C in a 150 ml wide-neck bottle (VWR no .: 807-001) using the Rheomat R 123 from proRheo. The Rheomat R 123 from proRheo GmbH is a rotational viscometer, ie a measuring body rotates in the substance to be measured. The force is measured that is required to make the measuring body rotate in the sample at a specified speed. The viscosity is calculated from this torque, the speed of the measuring body and the geometric dimensions of the measuring system used. The measuring body no.1 (article no. 2000191), suitable for a viscosity range up to 10,000 [mPa-s], speed range 62.5 min ^-1 , is used as the measuring body.

The formulations “according to the invention”, “advantageous according to the invention”, “advantageous within the meaning of the present invention” etc. relate in the context of the present disclosure always both to the preparation according to the invention and to the use according to the invention and to the method according to the invention.

If the term skin is used in the following, it refers exclusively to human skin.

If the term preparation is used below, it relates to the deodorant preparation according to the invention and to the preparation used according to the invention.

According to the invention, the preparation comprises zinc ricinoleate. Zinc ricinoleate is the zinc salt of ricinoleic acid, a main fatty acid contained in castor oil, which is obtained from the seeds of the Ricinus communis plant. Generally, zinc ricinoleate is known as an odor adsorbent. However, it has no bactericidal or fungicidal properties and therefore does not affect the natural flora of the skin.

The proportion of zinc ricinoleate in the preparation is advantageously from 0.42 to 2.25% by weight, preferably from 0.63 to 1.68% by weight and particularly preferably from 0.84 to 1.25% by weight , based on the total weight of the preparation.

The preparation according to the invention furthermore comprises at least one complexing agent. A complexing agent which can form a complex with zinc ions is advantageously chosen as the complexing agent. It is also advantageous if the complexing agent is selected from the group consisting of diethylenetriaminepentaacetic acid, ethylenediaminetetraacetic acid, ß-alaninediacetic acid, methylglycinediacetic acid, nitrilotriacetic acid, tetrasodium iminodisuccinate, tetrasodium-N, N-bis (carboxylatomethyl) -ethylenediaminic acid and tetrahydiamine-ethylenediaminic acid, ethylenediaminediamine propylene. It is preferred if the complexing agent is selected from the group consisting of ethylenediaminetetraacetic acid, tetrasodium-N, N-bis (carboxylatomethyl) -L-glutamate and tetrahydroxypropyl ethylenediamines. Tetrasodium N, N-bis (carboxylatomethyl) -L-glutamate is particularly preferably used as complexing agent.

The proportion of complexing agents is advantageously from 0.26% by weight to 1.9% by weight, preferably from 0.39% by weight to 1.28% by weight and particularly preferably from 0.49% by weight % to 0.85% by weight, based on the total weight of the preparation. It is also preferred if the proportion of complexing agents that can form a complex with zinc ions is from 0.26% by weight to 1.9% by weight, preferably from 0.39% by weight to 1.28% by weight .-% and particularly preferably from 0.49% by weight to 0.85% by weight, based on the total weight of the preparation.

It is also preferred if the total proportion of complexing agents is selected from the group consisting of diethylenetriaminepentaacetic acid, ethylenediaminetetraacetic acid, ß-alaninediacetic acid, methylglycinediacetic acid, nitrilotriacetic acid, tetrasodium iminodisuccinate, tetrasodium-N, N-bis (carboxylatomethylindylenediamine-bis (carboxylatomethylindyl) -hexylenediamine of tetrahydrofuran 26% by weight to 1.9% by weight, preferably from 0.39% by weight to 1.28% by weight and particularly preferably from 0.49% by weight to 0.85% by weight , based on the total weight of the preparation.

It is also preferred if the total proportion of complexing agents selected from the group of ethylenediaminetetraacetic acid, tetrasodium N, N-bis (carboxylatomethyl) -L-glutamate and tetrahydroxypropyl ethylenediamines from 0.26% by weight to 1.9% by weight, is preferably from 0.39% by weight to 1.28% by weight and particularly preferably from 0.49% by weight to 0.85% by weight, based on the total weight of the preparation.

It is also preferred if the complexing agent tetrasodium-N, N-bis (carboxylatomethyl) -L-glutamate in a proportion of 0.26% by weight to 1.9% by weight, preferably 0.39% by weight % to 1.28% by weight and particularly preferably from 0.49% by weight to 0.85% by weight, based on the total weight of the preparation. In this case it is also advantageous if, besides tetrasodium N, N-bis (carboxylatomethyl) -L-glutamate, no further complexing agents are contained.

Preferred embodiments of the invention are advantageously characterized in that the weight ratio of zinc ricinoleate to the total proportion of complexing agents is from 10: 1 to 1:10, preferably from 3: 1 to 1: 2 and particularly preferably from 2: 1 to 1: 1.

Furthermore, preferred embodiments of the invention are advantageously characterized in that the weight ratio of zinc ricinoleate to the total proportion of complexing agents is selected from the group consisting of diethylenetriaminepentaacetic acid, ethylenediaminetetraacetic acid, ß-alaninediacetic acid, methylglycinediacetic acid, nitrilotriacetic acid, tetrasodiumiminatomodisuccinate, sodium tetrasodium) bis - L-glutamate, ethylenediamine disuccinic acid and tetrahydroxypropyl ethylenediamine is from 10: 1 to 1:10, preferably from 3: 1 to 1: 2 and particularly preferably from 2: 1 to 1: 1. Furthermore, preferred embodiments of the invention are advantageously characterized in that the weight ratio of zinc ricinoleate to the total proportion of complexing agents selected from the group ethylenediaminetetraacetic acid, tetrasodium-N, N- bis (carboxylatomethyl) -L-glutamate and tetrahydroxypropyl ethylenediamine of 10: 1 to 1 : 10, preferably 3: 1 to 1: 2 and particularly preferably from 2: 1 to 1: 1.

Furthermore, preferred embodiments of the invention are advantageously characterized in that the weight ratio of zinc ricinoleate to the total proportion of tetrasodium N, N-bis (carboxylatomethyl) -L-glutamate is from 10: 1 to 1:10, preferably 3: 1 to 1: 2 and particularly preferably from 2: 1 to 1: 1.

The preparation according to the invention also comprises caprylyl / caprylic glucoside and / or sodium methyl cocoyl taurate. If caprylyl / caprylic glucoside is contained, the proportion of caprylyl / caprylic glucoside is preferably from 0.1 to 3% by weight, more preferably from 0.8 to 2.5% by weight and particularly preferably from 1.0 to 1.8% by weight, based in each case on the total weight of the preparation. If sodium methyl cocoyl taurate is contained, the proportion of sodium methyl cocoyl taurate is preferably from 0.1 to 1% by weight, more preferably from 0.15 to 0.8% by weight and particularly preferably from 0.25 to 0.4% by weight, based in each case on the total weight of the preparation. If both caprylyl / caprylic glucoside and sodium methyl cocoyl taurate are contained, the total proportion of both components in the preparation is preferably from 0.1 to 3% by weight, more preferably from 0.8 to 2.5% by weight and particularly preferably from 1.0 to 1.8% by weight, based in each case on the total weight of the preparation.

It is also advantageous if the preparation additionally contains a further alkyl glucoside, this being advantageously selected from the group consisting of cocoglucoside, lauryl glucoside and decyl glucoside. It is particularly preferred if decyl glucoside is additionally contained.

If at least one additional alkyl glucoside is present, the proportion of these additional alkyl glucosides is advantageously from 0.1 to 3% by weight, preferably from 0.2 to 2.58% by weight and particularly preferably from 0.35 to 1% by weight. -%, each based on the total weight of the preparation.

If it contains at least one additional alkyl glucoside selected from the group consisting of cocoglucoside, lauryl glucoside and decyl glucoside, the total proportion is this Alkyl glucosides advantageously from 0.1 to 3% by weight, preferably from 0.2 to 2.58% by weight and particularly preferably from 0.35 to 1% by weight, based in each case on the total weight of the preparation.

It is also advantageous if the preparation of the invention comprises at least one alkanediol. In general, it is advantageous if the total proportion of alkanediols is from 2.5 to 9% by weight, preferably from 3 to 8% by weight and particularly preferably from 4 to 7% by weight, based on the total weight of the preparation .

It is also advantageous in the context of the present invention if the preparation contains 1,3-butanediol (INCI: butylene glycol). If it contains 1,3-butanediol, it is preferred if the proportion of 1,3-butanediol is from 1 to 6% by weight, more preferably from 2 to 5% by weight and particularly preferably from 2.5 to 4% by weight .-%, based in each case on the total weight of the preparation. 1,3-Butanediol is not only advantageous for the present invention but also serves as a preservative aid in the specially present formulation.

It is also advantageous for the purposes of the present invention if the preparation contains 1,2 hexanediol and / or 1,2 octanediol. If it contains 1,2 hexanediol and / or 1,2 octanediol, it is preferred if the total proportion of 1,2 hexanediol and / or 1,2 octanediol is 0.3 to 1% by weight, further preferably 0.4 to 0.9% by weight and particularly preferably from 0.6 to 0.8% by weight, based in each case on the total weight of the preparation. 1,2 hexanediol and / or 1,2 octanediol are not only advantageous for the present invention but also serve as preservative helpers for the preservation of the formulation.

It is also advantageous for the purposes of the present invention if the preparation contains methylpropanediol. If methylpropanediol is included, it is preferred if the proportion of methylpropanediol is from 0.5 to 5% by weight, further preferably from 1 to 4% by weight and particularly preferably from 1.8 to 3% by weight, in each case based on the total weight of the preparation.

It is also advantageous for the purposes of the present invention if the preparation contains propane-1,3-diol. If it contains propane-1,3-diol, it is preferred if the proportion of propane-1,3-diol is from 0.04 to 0.32% by weight, more preferably from 0.12 to 0.24% by weight. -% and particularly preferably from 0.16 to 0.22% by weight, based in each case on the total weight of the preparation. It is also advantageous for the purposes of the present invention if the preparation additionally contains glycerol. If glycerin is contained, it is preferred if the proportion of glycerin is from 0.5 to 5% by weight, further preferably from 0.75 to 4% by weight and particularly preferably from 0.9 to 3% by weight , each based on the total weight of the preparation.

The preparation according to the invention is further characterized in that it advantageously comprises less than 1% by weight of ethanol, preferably less than 0.5% by weight and in particular less than 0.3% by weight of ethanol. According to the invention, the indication “less than a certain proportion” also means that the preparation according to the invention cannot contain any constituents of the substance.

It is also advantageous for the purposes of the present invention if the preparation additionally contains phenoxyethanol. If it contains phenoxyethanol, it is preferred if the proportion of phenoxyethanol is from 0.5 to 1.2% by weight, furthermore preferably from 0.6 to 1.0% by weight and particularly preferably from 0.7 to 0, 9% by weight, based in each case on the total weight of the preparation.

Furthermore, according to the invention, it was surprisingly possible to additionally incorporate thickening polymers without adversely affecting the transparency of the formula. The polymers xanthan gum and / or hydroxyethyl cellulose are preferred. If xanthan gum and / or hydroxyethyl cellulose are contained, their total proportion is advantageously 0.1% by weight to 0.5% by weight based on the total weight. Advantageously, no further polymeric thickeners are contained, since otherwise the viscosity of the preparation is set too high, so that application with a roll-on applicator is no longer possible.

The preparation of the invention may also contain one or more liquid fragrances. The term “liquid fragrances” refers to fragrances that are liquid under normal conditions. Liquid fragrances are typically a mixture of perfume or aromatic components, optionally mixed with a suitable solvent, diluent or carrier. Some or many of the perfume components, when combined, can result in a highly polar liquid fragrance. Some suitable solvents, diluents or carriers for the perfume or aromatic components can be ethanol, isopropanol, diethylene glycol monoethyl ether, dipropylene glycol, diethyl phthalate, triethyl citrate, isopropyl myristate, and mixtures thereof. The liquid fragrances can be selected from any natural or synthetic perfume component known to those skilled in the art of making fragrances. Some preferred examples of fragrance components are geraniol, geranyl acetate, linalool, linalyl acetate, tetrahydrolinalool, citronellol, citronellylacetate, dihydromyrcenol, dihydromyrcenyl acetate, tetrahydromyrcenol, terpineol, terpinylacetate, nopol, nopylacetate, 2-phenylethanol, 2-nopolyethanol. Phenylethyl acetate, benzyl alcohol, benzyl acetate, benzyl salicylate, benzyl benzoate, styrallyl acetate, amyl salicylate, dimethylbenzylcarbinol, trichloromethylphenylcarbinylacetate, p-tert.-butylcyclohexyl acetate, isononyl acetate, amononylacetate, 3-amyl-a-nyl-a-nyl-a-nylcine, methyl-hexylammic-a-nicydcine, methyl-3-hexylammic-a-nicydcine, alpha-nicydehydcine (p-tert-butylphenyl) propanol, 2-methyl-3- (p-isopropylphenyl) propanal, 3- (p-tert-butylphenyl) propanal, tricyclodecenyl acetate, tricyclodecenyl propionate, 4- (4-hydroxy-4-methylpentyl) -3-cyclohexenecarbaldehyde, 4- (4-methyl-3-pentenyl) -3-cyclohexenecarbaldehyde, 4-acetoxy-3-pentyltetrahydropyran, methyldihydrojasmonate, 2-n-heptylcyclopentanone, 3-methyl-2-pentylcyclopentanone, n-decanal, 9 -Decenol-1, phenoxyethyl isobutyrate, phenylacetaldehyde dimethyl acetal, phenylacetaldehyde diethyl acetal, geranonitrile, citronellonitrile, cedrylacetate, 3-isocamphylcyclohexanol, cedryl methyl ether, isolubine, heliotropine, coumarin, eugenol, vanillitronine, hylionone, isomethylionone, cis-3-hexenol and esters thereof, indane musk fragrances, tetralin musk fragrances, isochroman musk fragrances, ethylene brassylate and aromatic nitro musk fragrances. Other replaceable fragrances are described in Arctander, Perfume and Flavor Chemicals (Chemicals), Vol. I and II (1969) and in Arctander, Perfume and Flavor Materials of Natural Origin (1960).

The proportion of liquid fragrances, in particular the preferred liquid fragrances, in the preparation according to the invention is advantageously from 0.1 to 3% by weight, preferably 0.4 to 2% by weight, furthermore preferably from 0.5 to 1.5 % By weight and particularly preferably from 0.6 to 1.1% by weight, based in each case on the total weight of the preparation.

It is also advantageous if the cosmetic preparation contains water, the proportion of water preferably being from 78 to 90% by weight, more preferably from 80 to 88% by weight and particularly preferably from 82 to 87% by weight, where the information relates to the total weight of the preparation.

It is also advantageous in the context of the present invention if no silicone oils are contained. The cosmetic and dermatological preparations according to the invention can contain cosmetic auxiliaries such as are usually used in such preparations, for example preservatives, bactericides, antioxidants, minerals, suspended solid particles, perfumes, substances to prevent foaming, dyes, pigments that have a coloring effect , Thickeners, moisturizing and / or moisturizing substances or other common constituents of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers or silicone derivatives.

The preparation according to the invention is advantageously a deodorant preparation for use under the human armpit. The use of the cosmetic preparation as a deodorant is also according to the invention. The use of the cosmetic preparation under the human armpit to reduce and / or mask sweat odors is also according to the invention. According to the invention, there is also the provision of a cosmetic roll-on product consisting of a roll-on applicator containing the cosmetic deodorant preparation according to the invention, it being advantageous if the container of the roll-on applicator is transparent.

The preparation according to the invention advantageously has a viscosity in the range from 10 to 2000 mPas, preferably from 20 to 1000 mPas and particularly preferably from 50 to 150 mPas.

It is also advantageous if the pH of the preparation is from 5 to 10 and particularly advantageously from 7 to 9.

According to the invention, a preparation is regarded as transparent if it has a transmission of at least 85% at a wavelength of 600 nm. The measured transmission values are measured under normal conditions with a UV / VIS spectrometer UV / VIS Spectrometer Lambda 650 S (PerkinElmer) with a 150 mm integrating sphere in a quartz glass cuvette (Hellma precision cuvettes made of quartz glass Suprasil, type no. 100-QS) against a reference sample with distilled water . The slit width is 5 nm.

Comparative experiments and examples

The following examples are intended to illustrate the present invention without restricting it. Unless otherwise stated, all amounts, proportions and percentages are based on the weight and the total amount or on the total weight of the compositions. The following example formulations according to the invention were produced:

The recipes were produced on a laboratory scale in a beaker. For this purpose, all components with the exception of hydroxyethyl cellulose and xanthan gum were first combined and mixed. Then, in each case, hydroxyethyl cellulose and xanthan gum were added and stirring was continued until a homogeneous phase had formed.

In addition, the following reference examples not according to the invention were prepared:

Further sample recipes:

Claims

1. Aqueous cosmetic deodorant preparation comprising a. Zinc ricinoleate, b. At least one complexing agent, and c. Caprylyl / caprylic glucoside and / or sodium methyl cocoyl taurate.

2. Use of the combination of zinc ricinoleate, at least one complexing agent and at least one substance selected from caprylyl / caprylic glucoside and sodium methyl cocoyl taurate as a solubilizer in an aqueous cosmetic preparation.

3. Preparation according to claim 1 or use according to claim 2, characterized in that the proportion of zinc ricinoleate in the preparation is from 0.42 to 2.25% by weight, preferably from 0.63 to 1.68% by weight and in particular is preferably from 0.84 to 1.25% by weight, based on the total weight of the preparation.

4. Preparation or use according to one of the preceding claims, characterized in that the complexing agent selected is a complexing agent which can form a complex with zinc ions.

5. Preparation or use according to one of the preceding claims, characterized in that the complexing agent is selected from the group diethylenetriaminepentaacetic acid, ethylenediaminetetraacetic acid, ß-alaninediacetic acid, methylglycinediacetic acid, nitrilotriacetic acid, tetrasodium iminodisuccinate, tetrasodium-N, N-glutamethyl) bis (carboxyl) Ethylenediamine disuccinic acid and tetrahydroxypropyl ethylenediamine.

6. Preparation or use according to one of the preceding claims, characterized in that tetrasodium-N, N- bis (carboxylatomethyl) -L-glutamate is used as the complexing agent.

7. Preparation or use according to one of the preceding claims, characterized in that the proportion of complexing agents which can form a complex with zinc ions is from 0.26% by weight to 1.9% by weight, preferably from 0.39% by weight % to 1.28% by weight and particularly preferably from 0.49% by weight to 0.85% by weight, based on the total weight of the preparation.

8. Preparation or use according to one of the preceding claims, characterized in that the weight ratio of zinc ricinoleate to the total proportion of complexing agents from 10: 1 to 1:10, preferably 3: 1 to 1: 2 and particularly preferably from 2: 1 to 1: 1 is.

9. Preparation or use according to one of the preceding claims, characterized in that it contains caprylyl / caprylic glucoside and the proportion of caprylyl / caprylic glucoside is from 0.3 to 3% by weight, preferably from 0.8 to 2.5% by weight. -% and particularly preferably from 1.0 to 1.8% by weight, based in each case on the total weight of the preparation.

10. Preparation or use according to one of the preceding claims, characterized in that it contains sodium methyl cocoyl taurate and the proportion of sodium methyl cocoyl taurate is from 0.1 to 1% by weight, preferably from 0.15 to 0.8% by weight. -% and particularly preferably from 0.25 to 0.4% by weight, based in each case on the total weight of the preparation.

11. Preparation or use according to one of the preceding claims, characterized in that both caprylyl / caprylic glucoside and sodium methyl cocoyl taurate are included and the total proportion of both components in the preparation is 0.1 to 3% by weight, preferably 0, 8 to 2.5% by weight and particularly preferably from 1.0 to 1.8% by weight, based in each case on the total weight of the preparation.

12. Preparation or use according to one of the preceding claims, characterized in that the preparation additionally contains a further alkyl glucoside from the group consisting of cocoglucoside, lauryl glucoside and decyl glucoside.

13. Preparation or use according to claim 12, characterized in that the total proportion of alkyl glucosides selected from the group consisting of cocoglucoside, lauryl glucoside and decyl glucoside is 0.1 to 3% by weight, preferably 0.2 to 2.58% by weight and in particular is preferably from 0.35 to 1% by weight, based in each case on the total weight of the preparation.

14. Preparation or use according to one of the preceding claims, characterized in that it contains 1,3-butanediol, it being preferred if the proportion of 1,3-butanediol is from 1 to 6% by weight, further preferably from 2 to 5% by weight and particularly preferably from 2.5 to 4% by weight, based in each case on the total weight of the preparation.

15. Preparation or use according to one of the preceding claims, characterized in that it contains at least one liquid fragrance and the proportion of liquid fragrances in the preparation is advantageously from 0.1 to 3% by weight, preferably 0.4 to 2% by weight. -%, further preferably from 0.5 to 1.5% by weight and particularly preferably from 0.6 to 1.1% by weight, based in each case on the total weight of the preparation.